These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 35900853)

  • 1. Androgen receptor mutations for precision medicine in prostate cancer.
    Shiota M; Akamatsu S; Tsukahara S; Nagakawa S; Matsumoto T; Eto M
    Endocr Relat Cancer; 2022 Oct; 29(10):R143-R155. PubMed ID: 35900853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer.
    Wu M; Zhang R; Zhang Z; Zhang N; Li C; Xie Y; Xia H; Huang F; Zhang R; Liu M; Li X; Cen S; Zhou J
    Elife; 2023 Jan; 12():. PubMed ID: 36656639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.
    Coleman DJ; Van Hook K; King CJ; Schwartzman J; Lisac R; Urrutia J; Sehrawat A; Woodward J; Wang NJ; Gulati R; Thomas GV; Beer TM; Gleave M; Korkola JE; Gao L; Heiser LM; Alumkal JJ
    Oncotarget; 2016 Jun; 7(26):40690-40703. PubMed ID: 27276681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developing a Novel Enzalutamide-Resistant Prostate Cancer Model via AR F877L Mutation in LNCaP Cells.
    Wang R; Ma S; Xu N; Gan Y; Li P; Zhang J; Zhang Z; Gu Q; Xiang J
    Curr Protoc; 2024 Apr; 4(4):e1033. PubMed ID: 38652202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
    Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
    Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis.
    Sun R; Yan B; Li H; Ding D; Wang L; Pang J; Ye D; Huang H
    Cancer Res; 2023 Oct; 83(19):3192-3204. PubMed ID: 37527336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
    Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
    Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural and molecular insights into the mechanism of resistance to enzalutamide by the clinical mutants in androgen receptor (AR) in castration-resistant prostate cancer (CRPC) patients.
    Khan A; Mao Y; Tahreem S; Wei DQ; Wang Y
    Int J Biol Macromol; 2022 Oct; 218():856-865. PubMed ID: 35905763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
    Chung C; Abboud K
    Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.
    Wyatt AW; Azad AA; Volik SV; Annala M; Beja K; McConeghy B; Haegert A; Warner EW; Mo F; Brahmbhatt S; Shukin R; Le Bihan S; Gleave ME; Nykter M; Collins CC; Chi KN
    JAMA Oncol; 2016 Dec; 2(12):1598-1606. PubMed ID: 27148695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor splice variants in the era of enzalutamide and abiraterone.
    Nakazawa M; Antonarakis ES; Luo J
    Horm Cancer; 2014 Oct; 5(5):265-73. PubMed ID: 25048254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer.
    Ho Y; Dehm SM
    Endocrinology; 2017 Jun; 158(6):1533-1542. PubMed ID: 28368512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved therapeutic targeting of the androgen receptor: rational drug design improves survival in castration-resistant prostate cancer.
    Lim AC; Attard G
    Curr Drug Targets; 2013 Apr; 14(4):408-19. PubMed ID: 23565754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
    Crona DJ; Milowsky MI; Whang YE
    Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pinostilbene inhibits full-length and splice variant of androgen receptor in prostate cancer.
    Shin WS; Han SH; Jo KW; Cho Y; Kim KT
    Sci Rep; 2023 Oct; 13(1):16663. PubMed ID: 37794090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.
    Bernemann C; Schnoeller TJ; Luedeke M; Steinestel K; Boegemann M; Schrader AJ; Steinestel J
    Eur Urol; 2017 Jan; 71(1):1-3. PubMed ID: 27471164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.
    Wadosky KM; Koochekpour S
    Oncotarget; 2016 Sep; 7(39):64447-64470. PubMed ID: 27487144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and Synthesis of Dual-Target Inhibitors Targeting Androgen Receptors and Glucocorticoid Receptors to Overcome Antiandrogen Resistance in Castration-Resistant Prostate Cancer.
    Li C; Han X; Yan Q; Ji Y; Zhang R; Yuan D; Yang F; Wang J; Wu M; Zhou J
    J Med Chem; 2024 Mar; 67(5):3419-3436. PubMed ID: 38385428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.